Pfizer’s Ibrance (palbociclib) Fails to Meet its Primary Endpoint in P-lll PENELOPE-B Study for Early Breast Cancer

 Pfizer’s Ibrance (palbociclib) Fails to Meet its Primary Endpoint in P-lll PENELOPE-B Study for Early Breast Cancer

Pfizer’s Ibrance (palbociclib) Fails to Meet its Primary Endpoint in P-lll PENELOPE-B Study for Early Breast Cancer

Shots:

  • The P-lll PENELOPE-B study involves the assessment of Ibrance vs PBO in addition to at least 5yrs. of standard adjuvant endocrine therapy in 1,250 women with HR+, HER2- eBC at high risk of recurrence who have the residual invasive disease after completing neoadjuvant CT
  • The study did not meet its 1EPs of (iDFS) in women with eBC, no unexpected safety signals were observed. The trial is sponsored by the GBG as part of a clinical research collaboration with Pfizer and other study groups
  • Ibrance is an oral inhibitor of CDKs 4 and 6 and is approved in 95+ countries and has been prescribed to ~340,000 patients globally

    Click here ­to­ read full press release/ article | Ref: Pfizer | Image: TrialSite News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post